Details of the Drug Combination

General Information of Drug Combination (ID: DCTUOIW)

Drug Combination Name
Estramustine MK-5108
Indication
Disease Entry Status REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour Investigative [1]
Component Drugs Estramustine   DMWTAOI MK-5108   DMFGYKS
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: ES2
Zero Interaction Potency (ZIP) Score: 7.23
Bliss Independence Score: 12.31
Loewe Additivity Score: 19.62
LHighest Single Agent (HSA) Score: 9.77

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Estramustine
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [2]
Estramustine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Estramustine binding protein (EMBP) TTSBFYK NOUNIPROTAC Binder [4]
------------------------------------------------------------------------------------
Estramustine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [5]
------------------------------------------------------------------------------------
Estramustine Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Keratin, type I cytoskeletal 18 (KRT18) OTVLQFIP K1C18_HUMAN Increases Expression [6]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Increases Phosphorylation [7]
------------------------------------------------------------------------------------
Indication(s) of MK-5108
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
MK-5108 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aurora kinase B (AURKB) TT5LS6T AURKB_HUMAN Inhibitor [8]
Aurora kinase A (AURKA) TTPS3C0 AURKA_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Breast carcinoma DCK59SF OCUBM Investigative [9]
Carcinoma DC94B58 EFM192B Investigative [9]
Colon carcinoma DC77C9F RKO Investigative [9]
Adenocarcinoma DCROSU1 CAOV3 Investigative [10]
Adenocarcinoma DCFLH11 NCIH23 Investigative [10]
Adenocarcinoma DCR2FV7 COLO320DM Investigative [10]
Adenocarcinoma DC1VTGF DLD1 Investigative [10]
Adenocarcinoma DC2NERJ HT29 Investigative [10]
Amelanotic melanoma DCJ70UI A2058 Investigative [10]
Germ cell tumour DCZTFSZ PA1 Investigative [10]
Malignant melanoma DCGMPWJ A375 Investigative [10]
Malignant melanoma DCD30UN RPMI7951 Investigative [10]
Malignant melanoma DCRJN2P SKMEL30 Investigative [10]
Malignant melanoma DC6RPZ8 UACC62 Investigative [10]
Mesothelioma DCZU85E MSTO Investigative [10]
Ovarian endometrioid adenocarcinoma DCYIFMU A2780 Investigative [10]
Ovarian serous cystadenocarcinoma DCBIT89 SK-OV-3 Investigative [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 17 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 ClinicalTrials.gov (NCT00543387) Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001 AM4). U.S. National Institutes of Health.
4 Estramustine binding protein in primary tumours and metastases of malignant melanoma. Melanoma Res. 1994 Dec;4(6):401-5.
5 Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol. 2003 May;169(5):1729-34.
6 Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer. 2006 Jun 5;94(11):1592-8. doi: 10.1038/sj.bjc.6603129.
7 Induction of apoptosis by estramustine phosphate mediated by phosphorylation of bcl-2. J Neurooncol. 2001 Aug;54(1):23-9. doi: 10.1023/a:1012566601485.
8 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
9 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
10 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.